COVID-19 and post-COVID – Jekyll and Hyde of modern medicine
Authors:
Eliška Sovová 1; Samuel Genzor 2; Milan Sova 2,3; Markéta Sovová 1; Katarína Moravcová 2; Martin Šimek 4; Lenka Obare Pyzsková 5
Authors‘ workplace:
Klinika tělovýchovného lékařství a kardiovaskulární rehabilitace LF UP a FN Olomouc
1; Klinika plicních nemocí a tuberkulózy LF UP a FN Olomouc
2; Klinika nemocí plicních a tuberkulózy LF MU a FN Brno
3; Kardiochirurgická klinika, LF UP a FN Olomouc
4; Klinika anesteziologie, resuscitace a intenzivní medicíny, LF UP a FN Olomouc
5
Published in:
Vnitř Lék 2022; 68(4): 208-211
Category:
Main Topic
Overview
COVID-19 pandemic has massive impact on the whole world, lead to the death of milions of people and required excessive restrictions with large economical, psychological and other impacts. Post-COVID syndrome is defined according to the Czech pneumological and phtizeological society as a complex of symptoms persisting for more than 12 weeks from the acute stage of COVID-19 and which is not possible to explain by other causes. Exact pathopysiological mechanisms and its frequency are still not known, and the data from the literature are not consisent. We present case reports of 2 patients with very different disease and convalescence course. COVID-19 and post-COVID syndrome represent large space for the further research. The prediction of the persisting limitations and other consequencies of the diseases is still not possible. Even though there is usualy higher incidence of post-COVID symptoms in patients surviving severe COVID-19 course, the presented case reports show paradoxically exactly the oposite situation.
Keywords:
COVID-19 – case reports – post‑COVID
Sources
1. Kopecký P, Skála M, Neumannová K, Koblížek V. Post‑COVID syndrom/postižení; definice, diagnostika a klasifikace.Stručný poziční dokument ČPFS ČLS JEP. Dostupné na www.pneumologie. cz/guidelines/, online 29. 3. 2022.
2. Desai AD, Lavelle M, Boursiquot BC, Wan EY. Long‑term complications of COVID-19. Am J Physiol Cell Physiol. 2022;322(1):C1-c11.
3. Yong SJ. Long COVID or post‑COVID- 19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021;53(10):737-54.
4. Vance H, Maslach A, Stoneman E, Harmes K, Ransom A, Seagly K et al. Addressing Post‑COVID Symptoms: A Guide for Primary Care Physicians. J Am Board Fam Med. 2021;34(6):1229-42.
5. Cabrera Martimbianco AL, Pacheco RL, Bagattini  M, Riera R. Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review. Int J Clin Pract. 2021;75(10):e14357.
6. Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM et al. Fatigue and cognitive impairment in Post‑COVID- 19 Syndrome: A systematic review and meta‑analysis. Brain Behav Immun. 2022;101:93-135.
7. Fernández‑de‑Las‑Peñas C, Palacios‑Ceña D, Gómez‑Mayordomo V, Florencio LL, Cuadrado ML, Plaza‑Manzano G et al. Prevalence of post‑COVID- 19 symptoms in hospitalized and non‑hospitalized COVID-19 survivors: A systematic review and meta‑analysis. Eur J Intern Med. 2021;92:55-70.
8. Solomon JJ, Heyman B, Ko JP, Condos R, Lynch DA. CT of Post‑Acute Lung Complications of COVID-19. Radiology. 2021;301(2):E383-e95.
9. McDonald LT. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol. 2021;320(2):L257-l65.
10. Raman B, Bluemke DA, Lüscher TF, Neubauer S. Long COVID: post‑acute sequelae of COVID- 19 with a cardiovascular focus. Eur Heart J. 2022;43(11):1157-72.
11. Jartti T, Bønnelykke K, Elenius V, Feleszko W. Role of viruses in asthma. Semin Immunopathol. 2020 Feb;42(1):61-74.
12. Severin R, Arena R, Lavie CJ et al. Respiratory muscle performance screening for infectious disease management following COVID-19: a highly perssurized situation. Am J Med. 2020;133:1025-1032.
13. Gribensk A, Schneider A, Gallaher JR et al. Posthospitalization outcomes after extracorporeal membrane oxygenation (ECMO) for COVID-19. Surgery. 2022 Feb 8:S0039-6060(22)00076-9.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2022 Issue 4
Most read in this issue
- Development of recommendations for the use of venoactive drugs in the treatment of chronic venous disease – where they are effective and where they are not
- Acetylsalicylic acid in primary prevention of cardiovascular disease
- Urapidil: an unknown / known antihypertensive
- Acute kidney injury due to antimicrobial therapy